GRO Biosciences Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$60.3M
- Investors
-
19
GRO Biosciences General Information
Description
Developer of a protein therapeutics technology designed to develop improved treatments across multiple disease classes including diabetes, growth disorders, and autoimmunity. The company's technology utilizes computational protein design and synthetic biology and has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins, providing medical professionals with proteins that have increased potency, stability, and targeted delivery.
Contact Information
Website
www.grobio.comCorporate Office
- 750 Main Street
- Cambridge, MA 02139
- United States
Corporate Office
- 750 Main Street
- Cambridge, MA 02139
- United States
GRO Biosciences Timeline
GRO Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series B) | 19-Jul-2024 | $60.3M | Completed | Generating Revenue | ||
| 7. Later Stage VC (Series A) | 03-Nov-2021 | Completed | Generating Revenue | |||
| 6. Grant | 15-Sep-2020 | Completed | Generating Revenue | |||
| 5. Seed Round | 13-Mar-2019 | Completed | Generating Revenue | |||
| 4. Grant | 01-Feb-2019 | Completed | Generating Revenue | |||
| 3. Seed Round | 16-Aug-2017 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 13-Oct-2016 | Completed | Generating Revenue | |||
| 1. University Spin-Out | 01-Jan-2016 | Completed | Startup |
GRO Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Seed-1 | 7,138,773 | $0.000010 | 8% | $0.53 | $0.53 | 1x | $0.53 | 2.46% |
| Seed | 5,165,729 | $0.000010 | 8% | $0.46 | $0.46 | 1x | $0.46 | 1.78% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
GRO Biosciences Comparisons
Industry
Financing
Details
GRO Biosciences Competitors (90)
One of GRO Biosciences’s 90 competitors is American Gene Technologies, a Venture Capital-Backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| American Gene Technologies | Venture Capital-Backed | Rockville, MD | ||||
| Loxo Oncology | Formerly VC-backed | Stamford, CT | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Lycia Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA |
GRO Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
GRO Biosciences Patents
GRO Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210369818-A1 | Human dnase for lung disease | Inactive | 19-Nov-2018 | ||
| EP-3821003-A1 | Non-standard amino acid containing compositions and uses thereof | Pending | 09-Jul-2018 | ||
| CA-3106157-A1 | Non-standard amino acid containing compositions and uses thereof | Pending | 09-Jul-2018 | ||
| EP-3821003-A4 | Non-standard amino acid containing compositions and uses thereof | Pending | 09-Jul-2018 | ||
| US-20210371838-A1 | Non-standard amino acid containing compositions and uses thereof | Active | 09-Jul-2018 | C12Y301/21001 |
GRO Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
GRO Biosciences Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Access Biotechnology | Corporate Venture Capital | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| Page One Ventures | Venture Capital | Minority | ||
| Alumni Ventures | Venture Capital | Minority | ||
| Leaps by Bayer | Corporate Venture Capital | Minority |
GRO Biosciences FAQs
-
When was GRO Biosciences founded?
GRO Biosciences was founded in 2016.
-
Where is GRO Biosciences headquartered?
GRO Biosciences is headquartered in Cambridge, MA.
-
What is the size of GRO Biosciences?
GRO Biosciences has 35 total employees.
-
What industry is GRO Biosciences in?
GRO Biosciences’s primary industry is Biotechnology.
-
Is GRO Biosciences a private or public company?
GRO Biosciences is a Private company.
-
What is the current valuation of GRO Biosciences?
The current valuation of GRO Biosciences is .
-
What is GRO Biosciences’s current revenue?
The current revenue for GRO Biosciences is .
-
How much funding has GRO Biosciences raised over time?
GRO Biosciences has raised $91.4M.
-
Who are GRO Biosciences’s investors?
Access Biotechnology, Atlas Venture, Page One Ventures, Alumni Ventures, and Leaps by Bayer are 5 of 19 investors who have invested in GRO Biosciences.
-
Who are GRO Biosciences’s competitors?
American Gene Technologies, Loxo Oncology, CRISPR Therapeutics, Lycia Therapeutics, and ImmunityBio are some of the 90 competitors of GRO Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
